<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Reported-in-House" dms-id="H421E5FDF223148538CFB46DCF70A3D1D" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 4273 RH: Over-the-Counter Monograph Drug User Fee Amendments</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-09-17</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">IB</distribution-code><calendar display="yes">Union Calendar No. 254</calendar><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 4273</legis-num><associated-doc role="report" display="yes">[Report No. 119–300]</associated-doc><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250702">July 2, 2025</action-date><action-desc><sponsor name-id="L000566">Mr. Latta</sponsor> (for himself, <cosponsor name-id="D000197">Ms. DeGette</cosponsor>, <cosponsor name-id="C001120">Mr. Crenshaw</cosponsor>, and <cosponsor name-id="D000624">Mrs. Dingell</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><action display="yes"><action-date date="20250917">September 17, 2025</action-date><action-desc>Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed</action-desc><action-instruction>Strike out all after the enacting clause and insert the part printed in italic</action-instruction><action-instruction>For text of introduced bill, see copy of bill as introduced on July 2, 2025</action-instruction></action><action><action-desc><pagebreak></pagebreak></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes.<pagebreak></pagebreak></official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause" changed="added" style="OLC" committee-id="HIF00" reported-display-style="italic" id="H807FFE6158244F40825F60F15BF60F98"><section id="HE3DA7A331CFB455ABA9328354E326273" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title></quote>.</text></section><section id="H487E1F4F722F48D38C2E0E10931718B3"><enum>2.</enum><header>Finding</header><text display-inline="no-display-inline">Congress finds that the fees authorized by the amendments made in this Act will be dedicated to OTC monograph drug activities, as set forth in the goals identified for purposes of part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate, as set forth in the Congressional Record.</text></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="HFFEF604D07C64484830BC934D3D1B31C"><enum>3.</enum><header>Definitions</header><text display-inline="no-display-inline">Section 744L(9)(A) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71(9)(A)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H858691DFDD324149B1007E4596B46E20"><enum>(1)</enum><text>in clause (v), by striking <quote>; or</quote> and inserting a semicolon;</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H8250BC3A84724AC4B6E701633E6555BF"><enum>(2)</enum><text>in clause (vi)—</text><subparagraph id="HA4401EA98E2A4252B9D09E764970ABE3"><enum>(A)</enum><text>by striking <quote>addition</quote> and inserting <quote>the addition</quote>; and </text></subparagraph><subparagraph id="HA3F37E79E7DC4957AB099DDE823F9CD9"><enum>(B)</enum><text>by striking the period and inserting <quote>; or</quote>; and</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H01A35389B2874AB4A8333BC4BC14CE14"><enum>(3)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H8E6862A3F92B42DF8934326FC74F09A0" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="H434F2259E0B34DD5B2AC4319A830C8D0" indent="up1"><enum>(vii)</enum><text>the addition or modification of a testing procedure applicable to one or more OTC monograph drugs, provided that such additional or modified testing procedure reflects a voluntary consensus standard with respect to pharmaceutical quality that is—</text><subclause id="H4253D0B416BA4399A43B2EE356F81F81"><enum>(I)</enum><text>established by a national or international standards development organization; and</text></subclause><subclause id="H2CCA945B7C634D41A3F2BDCFB968AD7B" commented="no"><enum>(II)</enum><text display-inline="yes-display-inline">recognized by the Secretary through a process described in guidance for industry, initially published in July 2023, or any successor guidance, publicly available on the website of the Food and Drug Administration, which addresses voluntary consensus standards for pharmaceutical quality.</text></subclause></clause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section><section id="H989337D66D2141D1957927E715FE4500"><enum>4.</enum><header>Authority to assess and use OTC monograph fees</header><subsection commented="no" display-inline="no-display-inline" id="HC923DDB41B104E8EA059D8212C59852E"><enum>(a)</enum><header display-inline="yes-display-inline">Types of fees</header><text display-inline="yes-display-inline">Section 744M(a)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(a)(1)</external-xref>) is amended—</text><paragraph id="H1B3ED27F44C14AC8819A2B0E0609350B"><enum>(1)</enum><text>in subparagraph (A)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H5ED497112FE6402490E21271ABA1E5AE"><enum>(A)</enum><text>by striking <quote>on December 31 of the fiscal year or at any time during the preceding 12-month period</quote> and inserting <quote>at any time during the applicable period specified in clause (ii) for a fiscal year</quote>; </text></subparagraph><subparagraph id="HD56445BE41A74DFC8BE144809BA1B731"><enum>(B)</enum><text>by striking <quote>Each person</quote> and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H470CBF84AAA541E2B3743907B397D5A2" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="HC91A909F211549F88B27E7B6E116F6AF"><enum>(i)</enum><header>Assessment of fees</header><text>Each person</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HAF051BBFD72C43DB9BE141871203B8CC"><enum>(C)</enum><text>by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H53E61E16087645E0BC69CA5EE7F1CD44" changed="added" reported-display-style="italic" committee-id="HIF00"><clause id="HD52EC39563304B6B968B02E665A56E08"><enum>(ii)</enum><header>Applicable period</header><text>For purposes of clause (i), the applicable period is— </text><subclause commented="no" display-inline="no-display-inline" id="HC93FC66B7CEF4047997DAA327F6D4F31"><enum>(I)</enum><text display-inline="yes-display-inline">for fiscal year 2026, the 12-month period ending on December 31, 2025; </text></subclause><subclause id="H9C31EBA0A51D4DC2B9C5DB9AC6ADC8F8"><enum>(II)</enum><text>for fiscal year 2027, the 9-month period ending on September 30, 2026; and</text></subclause><subclause id="H7CFAF44016074B28BED1B86ED098E0F9"><enum>(III)</enum><text>for fiscal year 2028 and each subsequent fiscal year, the 12-month period ending on September 30 of the preceding fiscal year.</text></subclause></clause><after-quoted-block>; </after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H50B01E3925FE4EEDB5CB44C6D8FF38B0"><enum>(2)</enum><text>in subparagraph (B)(i), by amending subclause (I) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H7E9E2A23B3C9489EB76BA236F8B840C4" changed="added" reported-display-style="italic" committee-id="HIF00"><subclause id="H587361CB9DFE4D09A56467BC8EB2A069"><enum>(I)</enum><text>has ceased all activities related to OTC monograph drugs prior to—</text><item commented="no" display-inline="no-display-inline" id="H63C10CFB892F44F1B604DD5B3AD6CD3A"><enum>(aa)</enum><text>for purposes of fiscal year 2026, January 1, 2025;</text></item><item commented="no" display-inline="no-display-inline" id="H1E2A4025C0004A74BCEB81E6906F256A"><enum>(bb)</enum><text>for purposes of fiscal year 2027, January 1, 2026; and</text></item><item commented="no" display-inline="no-display-inline" id="H442AD419385E4C248537360D46F06D75"><enum>(cc)</enum><text>for purposes of fiscal year 2028 and each subsequent fiscal year, October 1 of the preceding fiscal year; and</text></item></subclause><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="H18875495B55B4365A7C535B93FF59806"><enum>(3)</enum><text>by amending subparagraph (D) to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H22F36559548F40A982EE5DCA2687A7F7" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H439340A3D81347528907DA47B231AE27"><enum>(D)</enum><header>Due date</header><clause commented="no" display-inline="no-display-inline" id="H9DCBE5E7FF694025B28A92C09FB23824"><enum>(i)</enum><header>Fiscal year 2026</header><text>For fiscal year 2026, the facility fees required under subparagraph (A) shall be due on the later of—</text><subclause commented="no" display-inline="no-display-inline" id="HBCDD298A24DC4BED97BA5F943EE237F7"><enum>(I)</enum><text display-inline="yes-display-inline">the first business day of June of such year; or</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H889C3646D33E4476A66DEF874C4A3231"><enum>(II)</enum><text>the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year.</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HB818EC919C1542198C14FCCB993580C9"><enum>(ii)</enum><header>Fiscal year 2027</header><text>For fiscal year 2027, the facility fees required under subparagraph (A) shall be due—</text><subclause commented="no" display-inline="no-display-inline" id="H40891C688F0541489248ADDC108C1384"><enum>(I)</enum><text>in a first installment representing 50 percent of such fee, on the later of—</text><item commented="no" display-inline="no-display-inline" id="HC6E3282299154F6CA4F9FE36D2974969"><enum>(aa)</enum><text display-inline="yes-display-inline">October 1, 2026; or </text></item><item id="HFF976D3F51A843F9A71475AEF4DDC568"><enum>(bb)</enum><text>the first business day after the enactment of an appropriations Act providing for the collection and obligation of fees under this section for such year; and</text></item></subclause><subclause commented="no" display-inline="no-display-inline" id="H8786D914D4F047058955B05176EBCE83"><enum>(II)</enum><text display-inline="yes-display-inline">in a second installment representing the remaining 50 percent of such fee, on—</text><item id="H3F5B09741F43469098ED4D895EE9C21F"><enum>(aa)</enum><text>February 1, 2027; or</text></item><item id="H39144A0F87F24679B74438AB373D5128"><enum>(bb)</enum><text>if an appropriations Act described in subclause (I)(bb) is not in effect on February 1, 2027, the first business day after enactment of such an appropriations Act.</text></item></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HBD57CDFE39674E9BB9DF8580AF335B4B"><enum>(iii)</enum><header>Subsequent fiscal years</header><text>For fiscal year 2028 and each subsequent fiscal year, the facility fees required under subparagraph (A) shall be due on the later of—</text><subclause id="H9E7A9ED1620A4E8AA9A8D505D9A6C306"><enum>(I)</enum><text>the first business day on or after October 1 of the fiscal year; or</text></subclause><subclause id="H8B6A18247BC2412F9F55D4CB5DAD97B9"><enum>(II)</enum><text>the first business day after the date of enactment of an appropriations Act providing for the collection and obligation of fees under this section for the fiscal year.</text></subclause></clause></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H6CC4954E6684478C9D48D231CEA085A1"><enum>(b)</enum><header>Fee revenue amounts</header><text>Section 744M(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(b)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HEBF1D10162514A4999307163D1BB4A5A" changed="added" reported-display-style="italic" committee-id="HIF00"><subsection id="H08904F2844C6409B8B34AF87C0394BF9" commented="no" display-inline="no-display-inline"><enum>(b)</enum><header display-inline="yes-display-inline">Fee revenue amounts</header><paragraph id="HAA59F7CA789B444AA1BF9F3EB787FC65"><enum>(1)</enum><header>In general</header><text>For each of the fiscal years 2026 through 2030, fees under subsection (a)(1) shall be established to generate a total facility fee revenue amount equal to the sum of—</text><subparagraph id="HA08522B5763542F78D9270243B68E3CE"><enum>(A)</enum><text>the annual base revenue for the fiscal year (as determined under paragraph (2));</text></subparagraph><subparagraph id="HE5F58BEB7D3A41808E03C79A4419FB74"><enum>(B)</enum><text>the dollar amount equal to the inflation adjustment for the fiscal year (as determined under subsection (c)(1)); </text></subparagraph><subparagraph id="H8F952891C1BB46D8A513FC167B7057CF"><enum>(C)</enum><text>the dollar amount equal to the operating reserve adjustment for the fiscal year, if applicable (as determined under subsection (c)(2)); </text></subparagraph><subparagraph id="H2FF92F47177D41F2A34817D750B470EB"><enum>(D)</enum><text>additional direct cost adjustments (as determined under subsection (c)(3));</text></subparagraph><subparagraph id="HA3B62EA784574C4DA845C0B196CE6DE4"><enum>(E)</enum><text>an additional dollar amount equal to—</text><clause id="H523982F634B146C09809B11E55B9D491"><enum>(i)</enum><text>$2,373,000 for fiscal year 2026;</text></clause><clause id="HA72517C7E2854E0EB9F0BEE73E351F45"><enum>(ii)</enum><text>$1,233,000 for fiscal year 2027; and</text></clause><clause id="HF7F91BB1671442278EDCFF92BF508D34"><enum>(iii)</enum><text>$854,000 for fiscal year 2028; and</text></clause></subparagraph><subparagraph id="H81C49774FB1D4E7993C65C045B4C6AD5"><enum>(F)</enum><text>in the case of a fiscal year for which the Secretary applies the one-time facility fee workload adjustment under subsection (c)(4), the dollar amount equal to such adjustment.</text></subparagraph></paragraph><paragraph id="H368586EA3E2A4180A70845AFE553F61C"><enum>(2)</enum><header>Annual base revenue</header><text>For purposes of paragraph (1), the dollar amount of the annual base revenue for a fiscal year shall be—</text><subparagraph id="H043D153EF70040A8BA5C9C230B6B1A18"><enum>(A)</enum><text>for fiscal year 2026, the dollar amount of the total revenue amount established for fiscal year 2025 under this subsection as in effect on the day before the date of enactment of the <short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title>, not including any adjustments made for such fiscal year 2025 under subsection (c)(2), as so in effect; and</text></subparagraph><subparagraph id="H594AD83EB50D4DC5BDB259AB76BAA82F"><enum>(B)</enum><text>for fiscal years 2027 through 2030, the dollar amount of the total revenue amount established under this subsection for the previous fiscal year, not including any adjustments made for such previous fiscal year under subsection (c)(2) or (c)(3).</text></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HD4019F2C258345D2B8E36E43B3E8D53C"><enum>(c)</enum><header>Adjustments; annual fee setting</header><text>Section 744M(c) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H617211E052684C99A5885D2D9055006A"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph commented="no" display-inline="no-display-inline" id="HDD35C50FA4E0470B82C4E45494C51305"><enum>(A)</enum><text>in subparagraph (A), in the matter preceding clause (i)—</text><clause commented="no" display-inline="no-display-inline" id="H9B8CA5E9E8AA4B3B8E2CD3A01E6E611C"><enum>(i)</enum><text>by striking <quote>subsection (b)(2)(B)</quote> and inserting <quote>subsection (b)(1)(B)</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H34C1D75066AF42A0B88E5E259A18CD57"><enum>(ii)</enum><text>by striking <quote>fiscal year 2022 and each subsequent fiscal year</quote> and inserting <quote>each fiscal year</quote>;</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HD5558456F4BB4832B97719C3E7E96754"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B), by striking <quote>fiscal year 2022</quote> and all that follows through the period at the end and inserting the following: </text><quoted-block style="OLC" id="H5DA43012EA5F477B93A3F652BB640453" display-inline="yes-display-inline" changed="added" reported-display-style="italic" committee-id="HIF00"><text>a fiscal year shall be equal to the product of—</text><clause id="H489C5B8D8BB54F9586FB1F46E719B616"><enum>(i)</enum><text>for fiscal year 2026—</text><subclause commented="no" display-inline="no-display-inline" id="H6168B1C5BACC4DAFB9B9563BBF3BD02C"><enum>(I)</enum><text>the fee for fiscal year 2025 under subsection (a)(2); and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H963C3CE1AEE0401188352DF4CFBDA648"><enum>(II)</enum><text display-inline="yes-display-inline">the inflation adjustment percentage under subparagraph (C); and</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="H484148455B3A419EB77E174DAB811958"><enum>(ii)</enum><text display-inline="yes-display-inline">for each of fiscal years 2027 through 2030—</text><subclause commented="no" display-inline="no-display-inline" id="H2D0092BE700347DC9DCE5514FF52EB0A"><enum>(I)</enum><text display-inline="yes-display-inline">the applicable fee under subsection (a)(2) for the preceding fiscal year; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H1D29E60727174991A40275B3531ECC18"><enum>(II)</enum><text display-inline="yes-display-inline">the inflation adjustment percentage under subparagraph (C).</text></subclause></clause><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H2C0E24912E564299A7CC58A02D4E181B"><enum>(C)</enum><text>in subparagraph (C)—</text><clause commented="no" display-inline="no-display-inline" id="H3A49554372A94BB980F01B92A7D83F53"><enum>(i)</enum><text>in the matter preceding clause (i), by inserting <quote>the sum of</quote> after <quote>is equal to</quote>;</text></clause><clause commented="no" display-inline="no-display-inline" id="H5526F7B54062422AB86502C18BA3752C"><enum>(ii)</enum><text display-inline="yes-display-inline">by striking clause (i);</text></clause><clause commented="no" display-inline="no-display-inline" id="HDB06A01B0AAD41388D54B63DDCD6D890"><enum>(iii)</enum><text>by redesignating subclauses (I) and (II) of clause (ii) as clauses (i) and (ii), respectively, and adjusting the margins accordingly;</text></clause><clause commented="no" display-inline="no-display-inline" id="H561E3AA71631473EAA7B99ED6ADFD871"><enum>(iv)</enum><text>by striking <quote>(ii) for each of fiscal years 2024 and 2025, the sum of—</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="HA786C05094C04DA9AB593ADEA1B98589"><enum>(v)</enum><text>in clause (ii), as so redesignated, by striking <quote>Washington-Baltimore, DC–MD–VA–WV</quote> and inserting <quote>Washington–Arlington–Alexandria–DC–VA–MD–WV</quote>;</text></clause></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HBDCC56DC86714EB79F27C6A06E515C2C"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H62AE44AEF47C4AC8BB914EA35DE2BCA2"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A)—</text><clause commented="no" display-inline="no-display-inline" id="HEC587FC1CE494683BF3C0D1A4573D9EB"><enum>(i)</enum><text display-inline="yes-display-inline">by striking <quote>fiscal year 2021 and subsequent fiscal years</quote> and inserting <quote>each fiscal year</quote>; </text></clause><clause commented="no" display-inline="no-display-inline" id="H40C5F5823F5B41828EB9538AD8C144EB"><enum>(ii)</enum><text>by striking <quote>subsections (b)(1)(B) and (b)(2)(C)</quote> and inserting <quote>subsection (b)(1)(C)</quote>; and</text></clause><clause commented="no" display-inline="no-display-inline" id="H9380E1D509434188971F3BC3045CBDAC"><enum>(iii)</enum><text>by striking <quote>the number of weeks specified in subparagraph (B)</quote> and inserting <quote>10 weeks</quote>;</text></clause></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HC94B91082A744936B66642E8C753F2F0"><enum>(B)</enum><text>by striking subparagraph (B);</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H3DB7F1D3F9A2452AAAB49B42DB4DB704"><enum>(C)</enum><text>by redesignating subparagraphs (C) and (D) as subparagraphs (B) and (C), respectively; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HB51F71A949DB47EBB29454AB679A2514"><enum>(D)</enum><text>in subparagraph (C), as so redesignated, by striking <quote>paragraph (4) establishing</quote> and inserting <quote>paragraph (5) publishing</quote>;</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HEFADE0BC7F174CC0889E9744B35AFC6E"><enum>(3)</enum><text>in paragraph (3)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H63376653DB5B4AA195152DF92388C7AB"><enum>(A)</enum><text display-inline="yes-display-inline">in the matter preceding subparagraph (A), by striking <quote>subsection (b)(2)(D)</quote> and inserting <quote>subsection (b)(1)(D)</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HB2F1B96CB95747EDB15FE86CAA9E7123"><enum>(B)</enum><text>by striking subparagraphs (A) through (E) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="H7293F3F2E0E44613AFBD352386ABF865" changed="added" reported-display-style="italic" committee-id="HIF00"><subparagraph id="H45F07A69CD7243CE9433C053837EC065"><enum>(A)</enum><text>$135,000 for fiscal year 2026;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HD944F9729B9D451985E3DB000293CC9C"><enum>(B)</enum><text>$300,000 for fiscal year 2027;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HAAF76C501B2F45C1954F27C8FCFCF6F9"><enum>(C)</enum><text>$55,000 for fiscal year 2028;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HD076F477272B4213AE02477A70862459"><enum>(D)</enum><text>$30,000 for fiscal year 2029; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H50137DE67EC544C58F7535D9A249FA2B"><enum>(E)</enum><text>$0 for fiscal year 2030.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="HDC5096A28C05432EB5F652F64B0BC2F3"><enum>(4)</enum><text>by striking paragraph (4) and inserting the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HBAFB591FFBAF4D5BBE3B9C861355478B" changed="added" reported-display-style="italic" committee-id="HIF00"><paragraph id="H03A95A8AE3E9420F9FEF09CC808F039F"><enum>(4)</enum><header>One-time facility fee workload adjustment</header><subparagraph commented="no" display-inline="no-display-inline" id="H9B8D791EACF5457CA2847E13A900C8D6"><enum>(A)</enum><header display-inline="yes-display-inline">In general</header><text>In addition to the adjustments under paragraphs (1), (2), and (3), the Secretary may further increase the fee revenues and fees through a one-time adjustment made for fiscal year 2028, 2029, or 2030, in accordance with this paragraph.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H28BFBD1716A0402280E09C7F5659480F"><enum>(B)</enum><header>Adjustment described</header><clause commented="no" display-inline="no-display-inline" id="H79A192C1686F45B9A657F40DD2F1B949"><enum>(i)</enum><header>Conditions for adjustment</header><text display-inline="yes-display-inline">An adjustment under this paragraph may be made for a fiscal year only if—</text><subclause commented="no" display-inline="no-display-inline" id="H5196F7FAF3494586A9890563E428A003"><enum>(I)</enum><text display-inline="yes-display-inline">an adjustment under this paragraph had not been made for any prior fiscal year;</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HF6D3B35F6D134B06A00FDF299312B65E"><enum>(II)</enum><text display-inline="yes-display-inline">the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the period of the preceding 3 fiscal years exceeds 1,625; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HC78D5C464AAE40F09252222615D04B92"><enum>(III)</enum><text display-inline="yes-display-inline">with respect to facilities described in subclause (II), the average number of such facilities (expressed as a percentage) that appeared on the arrears lists pursuant to subsection (e)(1)(A)(i) over the period of the preceding 3 fiscal years is less than 30 percent.</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="H2BCA399ED25E4FD2941D93C34F5D4084"><enum>(ii)</enum><header>Amount of adjustment</header><text display-inline="yes-display-inline">An adjustment under this paragraph for a fiscal year shall equal the product of—</text><subclause commented="no" display-inline="no-display-inline" id="H73F31420E20F4221AFE5E3B415BF088E"><enum>(I)</enum><text display-inline="yes-display-inline">the total facility revenue amount determined under subsection (b) for the fiscal year, exclusive of the adjustment under this paragraph for such fiscal year; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HA8B67DDC844F4BB983A3260B56DD949D"><enum>(II)</enum><text display-inline="yes-display-inline">the excess facility percentage described in clause (iii).</text></subclause></clause><clause commented="no" display-inline="no-display-inline" id="HE16CC6F1704F479D9E22CC8AA62A1EE2"><enum>(iii)</enum><header>Excess facility percentage</header><text display-inline="yes-display-inline">The excess facility percentage described in this clause is—</text><subclause commented="no" display-inline="no-display-inline" id="H86DAEB8AEABB4ABFB056C589BC7760A9"><enum>(I)</enum><text display-inline="yes-display-inline">the amount by which the average number of OTC monograph drug facilities subject to a facility fee under subsection (a)(1) over the preceding 3 fiscal years exceeds 1,625; divided by</text></subclause><subclause commented="no" display-inline="no-display-inline" id="H71038FAAE7E0410591A8B4517D4EDCE1"><enum>(II)</enum><text display-inline="yes-display-inline">1,625.</text></subclause></clause></subparagraph></paragraph><paragraph id="HA558B66EEB424FB38C25E6FA265D3EA5" display-inline="no-display-inline"><enum>(5)</enum><header>Annual fee setting</header><text>The Secretary shall, not later than 60 days before the first day of each fiscal year—</text><subparagraph id="HF1F7554303E7469987FA1033388C9C3E" commented="no" display-inline="no-display-inline"><enum>(A)</enum><text>establish for such fiscal year, based on the revenue amounts under subsection (b) and the adjustments provided under this subsection—</text><clause id="HE2B04C7A12C348AD947C66D0E2AB3DCD" commented="no" display-inline="no-display-inline"><enum>(i)</enum><text display-inline="yes-display-inline">OTC monograph drug facility fees under subsection (a)(1); and</text></clause><clause id="H32EC7AF860D9452A84DE7C093E05BA1B" commented="no" display-inline="no-display-inline"><enum>(ii)</enum><text>OTC monograph order request fees under subsection (a)(2); and</text></clause></subparagraph><subparagraph id="HD7C90555BFBC46F8B44B6FEFC5D6F8AC" commented="no" display-inline="no-display-inline"><enum>(B)</enum><text display-inline="yes-display-inline">publish such fee revenue amounts, facility fees, and OTC monograph order request fees in the Federal Register.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection commented="no" display-inline="no-display-inline" id="H6756278D19DD49379D4E9376D2DB3FB5"><enum>(d)</enum><header>Crediting and availability of fees</header><text>Section 744M(f) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-72">21 U.S.C. 379j–72(f)</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="H46DB2EC72F734D8E98414C861FD71CAB"><enum>(1)</enum><text>in paragraph (2)(D)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H3F4946CF41B445198245BC65572567D4"><enum>(A)</enum><text>in the subparagraph heading, by striking <quote><header-in-text style="OLC" level="subparagraph">in subsequent years</header-in-text></quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="HF3BE81D1E2904C8D877B28B7292881C6"><enum>(B)</enum><text>by striking <quote>(after fiscal year 2021)</quote>; and</text></subparagraph></paragraph><paragraph id="H4CA0E417CB0F49708FE60B6DEFCCDAE7"><enum>(2)</enum><text>in paragraph (3), by striking <quote>2021 through 2025</quote> and inserting <quote>2026 through 2030</quote>.</text></paragraph></subsection></section><section commented="no" display-inline="no-display-inline" id="HADBF511079F54B04A2734B5EF7D6C7F6"><enum>5.</enum><header>Reauthorization; reporting requirements</header><text display-inline="no-display-inline">Section 744N of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-73">21 U.S.C. 379j–73</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="HA624BB0667BD4774A837E1C282E37924"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H22AF96647620408BBE498B08F570AA66"><enum>(A)</enum><text>by striking <quote>Beginning with fiscal year 2021, and not later than 120 calendar days after the end of each fiscal year thereafter</quote> and inserting <quote>Not later than 120 calendar days after the end of each fiscal year</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H69675E9F39E7465E95436AC43CDE578D"><enum>(B)</enum><text>by striking <quote>section 3861(b) of the CARES Act</quote> and inserting <quote>section 2 of the <short-title>Over-the-Counter Monograph Drug User Fee Amendments</short-title></quote>;</text></subparagraph></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H5DB6E32FD8294F3590CD8D06A131B9FE"><enum>(2)</enum><text>in subsection (b), by striking <quote>fiscal year 2021 and each subsequent fiscal year</quote> and inserting <quote>each fiscal year</quote>; and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="H1CC107E62CED4B82B549A887BD69B94C"><enum>(3)</enum><text>in subsection (d), by striking <quote>2025</quote> each place it appears and inserting <quote>2030</quote>.</text></paragraph></section><section id="HCDF56B4326BE479D97188E67E78F4E13" commented="no"><enum>6.</enum><header>Regulation of certain nonprescription drugs that are marketed without an approved drug application</header><subsection id="HE36422AD80624042B191298F08270DA5" commented="no"><enum>(a)</enum><header>Development advice to sponsors or requestors</header><text display-inline="yes-display-inline">Section 505G(h) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355h">21 U.S.C. 355h(h)</external-xref>) is amended by striking <quote>sponsors or requestors</quote> and inserting <quote>sponsors, requestors, or organizations nominated by sponsors or requestors to represent their interests in a proceeding</quote>.</text></subsection><subsection id="H52F5CA95749646D79543990AFC38A207" commented="no"><enum>(b)</enum><header>Technical correction</header><text display-inline="yes-display-inline">Section 505G(b)(2)(A)(iv)(III) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355h">21 U.S.C. 355h(b)(2)(A)(iv)(III)</external-xref>) is amended by striking <quote>requestors</quote> and inserting <quote>sponsors or requestors</quote>. </text></subsection></section><section commented="no" display-inline="no-display-inline" id="H35879F9C034E466C98B6B460B3020D17"><enum>7.</enum><header>Sunset dates</header><subsection id="H1C5787326C6C4ADB89C8D46266F206A6"><enum>(a)</enum><header>Authorization</header><text display-inline="yes-display-inline">Sections 744L and 744M of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71</external-xref>; 379j–72) shall cease to be effective October 1, 2030. </text></subsection><subsection id="HC69A852AA61744BB9ADD37A78692FFEF"><enum>(b)</enum><header>Reporting requirements</header><text>Section 744N of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-73">21 U.S.C. 379j–73</external-xref>) shall cease to be effective January 31, 2031.</text></subsection></section><section id="HD5720ECF752249A3BBF3251913BB1B30"><enum>8.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this Act shall take effect on October 1, 2025, or the date of the enactment of this Act, whichever is later, except that fees under part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>) shall be assessed beginning October 1, 2025, regardless of the date of the enactment of this Act.</text></section><section commented="no" display-inline="no-display-inline" section-type="subsequent-section" id="H99E4F53BA48C486EBC74A72623B21313"><enum>9.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this Act, part 10 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-71">21 U.S.C. 379j–71 et seq.</external-xref>), as in effect on the day before the date of enactment of this Act, shall continue to be in effect with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2026.</text></section></legis-body><endorsement display="yes"><action-date date="20250917">September 17, 2025</action-date><action-desc>Reported with an amendment, committed to the Committee of the Whole House on the State of the Union, and ordered to be printed</action-desc></endorsement></bill> 

